• Bart S. Ferket, Gorav Ailawadi, Annetine C. Gelijns, Michael Acker, Samuel F. Hohmann, Helena L. Chang, Denis Bouchard,, David O. Meltzer, Robert E. Michler, Ellen G. Moquete, Pierre Voisine, John C. Mullen, Anuradha Lala, Michael J. Mack, A. Marc Gillinov, Vinod H. Thourani, Marissa A. Miller, James S. Gammie, Michael K. Parides, Emilia Bagiella, Robert L. Smith, Peter K. Smith, Judy W. Hung, Lopa N. Gupta, Eric A. Rose, Patrick T. O'Gara, Alan J. Moskowitz, and Cardiothoracic Surgical Trials Network (CTSN) Investigators.
• Circ Cardiovasc Qual. 2018 Nov 14; 11 (11): e004466.

BackgroundThe CTSN (Cardiothoracic Surgical Trials Network) recently reported no difference in left ventricular end-systolic volume index or in survival at 2 years between patients with severe ischemic mitral regurgitation (MR) randomized to mitral valve repair or replacement. However, replacement provided more durable correction of MR and fewer cardiovascular readmissions. Yet, costeffectiveness outcomes have not been addressed.Methods And ResultsWe conducted a cost-effectiveness analysis of the surgical treatment of ischemic MR based on the CTSN trial (n=126 for repair; n=125 for replacement). Patient-level data on readmissions, survival, qualityof- life, and US hospital costs were used to estimate costs and quality-adjusted life years per patient over the trial duration and a 10-year time horizon. We performed microsimulation for extrapolation of outcomes beyond the 2 years of trial data. Bootstrap and deterministic sensitivity analyses were done to address parameter uncertainty. In-hospital cost estimates were $78 216 for replacement versus $72 761 for repair (difference: $5455; 95% uncertainty interval [UI]: −7784–21 193) while 2-year costs were $97 427 versus $96 261 (difference: $1166; 95% UI: −16 253–17 172), respectively. Quality-adjusted life years at 2 years were 1.18 for replacement versus 1.23 for repair (difference: −0.05; 95% UI: −0.17 to 0.07). Over 5 and 10 years, the benefits of reduction in cardiovascular readmission rates with replacement increased, and survival minimally improved compared with repair. At 5 years, cumulative costs and quality-adjusted life years showed no difference on average, but by 10 years, there was a small, uncertain benefit for replacement: $118 023 versus $119 837 (difference: −$1814; 95% UI: −27 144 to 22 602) and qualityadjusted life years: 4.06 versus 3.97 (difference: 0.09; 95% UI: −0.87 to 1.08). After 10 years, the incremental cost-effectiveness of replacement continued to improve.ConclusionsOur cost-effectiveness analysis predicts potential savings in cost and gains in quality-adjusted survival at 10 years when mitral valve replacement is compared with repair for severe ischemic MR. These projected benefits, however, were small and subject to variability. Efforts to further delineate predictors of long-term outcomes in patients with severe ischemic MR are needed to optimize surgical decisions for individual patients, which should yield more cost-effective care.Clinical Trial RegistrationURL: https://www.clinicaltrials.gov. Unique identifier: NCT00807040.2018 American Heart Association, Inc.

39 keywords...

hide…